News Releases Year: All News2020201920182017201620152014201320122011 Items per page All News2550 August 4, 2015 Summary ToggleAllena Pharmaceuticals Initiates Phase 2b Trial of ALLN-177 for Secondary Hyperoxaluria Read more April 16, 2015 Summary ToggleAllena Pharmaceuticals Appoints Louis Brenner, M.D. as Chief Operating Officer Read more March 18, 2015 Summary ToggleAllena Pharmaceuticals Announces Positive Phase 2a Data of ALLN-177 for the Treatment of Hyperoxaluria Read more January 8, 2015 Summary ToggleAllena Pharmaceuticals to Present at 2015 J.P. Morgan Healthcare Conference Read more December 4, 2014 Summary ToggleAllena Pharmaceuticals Secures $25 Million Series B Financing Read more November 17, 2014 Summary ToggleAllena Pharmaceuticals Presents Phase 1 Data on ALLN-177 at American Society of Nephrology Kidney Week 2014 Read more November 10, 2014 Summary ToggleAllena Pharmaceuticals To Present Data on Lead Program ALLN-177 at ASN Kidney Week 2014 Read more April 29, 2014 Summary ToggleAllena Pharmaceuticals Announces Positive Phase 1 Data of ALLN-177 for the Treatment of Kidney Stones Read more January 13, 2014 Summary ToggleAllena Pharmaceuticals to Present at the 2014 J.P. Morgan Healthcare Conference Read more March 28, 2012 Summary ToggleAllena Pharmaceuticals Licenses Worldwide Rights to Hyperoxaluria Portfolio from Althea Technologies Read more Pagination First page First Previous page Previous … Page 5 Page 6 Current page 7 Page 8 Next page Next Last page Last
